LifeTech Scientific

LifeTech Scientific (Shenzhen) Co., Ltd. ("LifeTech Scientific") is a leading enterprise in minimally invasive interventional medical devices for cardiovascular, cerebrovascular, and peripheral vascular diseases. Founded in Shenzhen, China in 1999, it was listed on the Hong Kong Stock Exchange in 2011 (stock code: 1302.HK). The company's innovative product portfolio with independent intellectual property rights covers structural heart disease, peripheral vascular disease, cardiac rhythm management, oncology, and respiratory intervention, and it possesses the world's first iron-based bioabsorbable biomaterial platform, achieving technological breakthroughs in multiple niche fields. Its high-quality independently innovative products are rooted in China and sold in over 100 countries and regions worldwide. LifeTech Scientific consistently invests 20% or more of its sales revenue in R&D and innovation, holds nearly 1,400 high-quality patents, and has had 13 products approved by NMPA for inclusion in the "Innovative Medical Device Special Review Program". The company was rated as a "High-tech Enterprise" in 2008, recognized as a Guangdong Province Specialized and Sophisticated Enterprise in 2020, and awarded the national MIIT "Little Giant" Enterprise title in 2021. It is one of the founding shareholders of the National High-Performance Medical Device Innovation Center, possesses high-level research qualifications such as the "National and Local Joint Engineering Laboratory" and the "National Postdoctoral Research Workstation", undertakes over 50 government research projects including the National "Tenth Five-Year" Science and Technology Research Program, the National "973" Plan, and the National "863" Plan, and actively participates in the drafting and formulation of various industry standards. LifeTech Scientific adheres to the integrated scientific development of production, education, research, and application, collaborating with industry doctors, research institutions, and outstanding innovative minds to tackle technical bottlenecks. Through independent innovation, it brings safe and effective clinical treatment methods to doctors, better disease solutions to patients, promotes high-quality innovative development in the industry, and leads Chinese medical technology to serve the world.